Human α 1 -antitrypsin (α 1 -AT) is a natural inhibitor of neutrophil elastases and has several dozens of genetic variants. Most of the deficient genetic variants of human α 1 -AT are unstable and cause pulmonary emphysema. However, the most clinically significant variant, Z-type α 1 -AT, exhibits retarded protein folding that leads to accumulation of folding intermediates. These aggregate within the endoplasmic reticulum (ER) of hepatocytes, subsequently causing liver cirrhosis as well as emphysema. Here, we studied the role of an ER folding assistant protein Cpr5p on Z-type α 1 -AT folding. Cpr5p was induced > 2-fold in Z-type α 1 -AT-expressing yeast cells compared with the wild type. Knockout of CPR5 exacerbated cytotoxicity of Z-type α 1 -AT, and re-introduction of CPR5 rescued the knockout cells from aggravated cytotoxicity caused by the α 1 -AT variant. Furthermore, Cpr5p co-immunoprecipitated with Z-type α 1 -AT and facilitated its protein folding. Our results suggest that protein-folding diseases may be suppressed by folding assistant proteins at the site of causal protein biosynthesis.
Introduction α 1 -Antitrypsin (α 1 -AT) is a prototypical member of the serine protease inhibitor (serpin) superfamily 1 that includes several protease inhibitors, such as α 1 -antichymotrypsin, antithrombin-III, C1 inhibitor, and plasminogen activator inhibitor-1. Serpin shares a common tertiary structure composed of a mobile reactive center loop (RCL), three β-sheets, and several α-helices.
2 When these enzymes inhibit target proteases, the metastable native form of serpins facilitates insertion of the RCL into β-sheet A. 3 However, incorporation of metastable intramolecular interactions during the folding process makes serpin molecules vulnerable to folding defects, 4 and more than 100 genetic variants of serpins have been reported. 5 α 1 -AT is synthesized in the liver and secreted into plasma to protect tissues against indiscriminate proteolytic attacks from neutrophil elastases. 6 Many dysfunctional genetic variants of α 1 -AT cause an imbalance between serum proteases and their inhibitors, causing serious clinical problems, such as emphysema. 3 Most of the dysfunctional α 1 -AT variants show conformational instability and fold into loosely packed structures prone to aggregation. 7 During inflammation, elevated body temperature can exacerbate α 1 -AT polymerization, leading to the onset of clinical symptoms indicative of α 1 -AT deficiency.
8 Z-type α 1 -AT (Glu 342 → Lys) is the most clinically significant α 1 -AT variant, affecting 1 in 1,800-2,000 live births, and 8-10% of homozygotes develop liver cirrhosis. 9, 10 In contrast to other variants, the molecular basis of the Z-type variant deficiency was identified as severely retarded protein folding, 11 which leads to the accumulation of folding intermediates with a high tendency to polymerize at the site of biosynthesis in the endoplasmic reticulum (ER) of hepatocytes, causing liver cirrhosis as well as emphysema. Once folded, the native form of the Z-type α 1 -AT variant showed considerable stability and activity. Thus, facilitating folding of this α 1 -AT variant might be a viable approach to prevent onset of clinical symptoms.
Folding assistant proteins, including molecular chaperones, facilitate proper folding of newly synthesized polypeptide chains, assembly of subunits and transport of the polypeptide into the correct cellular compartments. Some folding assistant proteins, such as protein disulfide isomerases and peptidylprolyl isomerases (PPIases), have enzymatic activity that accelerates the rate limiting steps of protein folding.
12 Since α 1 -AT has no disulfide bond, the enzymatic activity of protein disulfide isomerases is not likely to contribute to the folding of Z-type α 1 -AT. However, α 1 -AT has 17 X-Pro peptide bonds out of 393 total peptidyl bonds, which may limit the folding rate of the protein, and the level of PPIases was shown to be elevated in Z-type α 1 -AT expressing yeasts.
PPIases accelerate the rate-determining proline cis-trans isomerization steps in protein folding. 13, 14 They are classified into three major groups: the cyclophilins, the FK506-binding proteins (FKBPs), and the parvulins. Cyclophilins were originally discovered as cellular targets that bind with high affinity to the immunosuppressive drug cyclosporin A, hCyp40, and hCypNK. 22 After cytosolic hCypA, hCypB is the second most abundant cyclophilin, with an N-terminal signal sequence that targets the protein to the ER, where it localizes mainly in the lumen. 23 An ER stress response element (ERSE), a consensus sequence necessary for transactivation of genes encoding ER chaperones during the unfolded protein response (UPR), is located upstream of the hCypB ORF. Indeed, ER protein misfolding induced by tunicamycin, an inhibitor of N-linked protein glycosylation, increased the expression of hCypB approximately two-fold. 24 Meanwhile, overexpression of hCypB attenuated ER stress-induced apoptosis. 24 There are several studies showing that ER cyclophilin(s) are required for proper folding of secreted or membrane proteins, including Drosophila cyclophilin ninaA, which is required for the secretion of rhodopsin. 25 In addition, treatment of chicken embryo tendon fibroblasts with cyclosporin A inhibits the proper folding of procollagen I.
26
Yeast is a good model system to study the function(s) of a particular protein, due to the availability of high throughput genetic screening and accumulation of large amounts of biochemical and genetic information. Saccharomyces cerevisiae has eight different cyclophilins (Cpr1p-Cpr8p), 22 and Cpr5p, a yeast homologue of hCypB, is also localized in the ER.
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To study whether the folding defects of Z-type α 1 -AT could be remedied by Cpr5p, human wild-type and Z-type α 1 -AT were each overexpressed in S. cerevisiae. Expression of Cpr5p was induced more than two-fold in cells expressing Z-type α 1 -AT compared with those expressing wild-type α 1 -AT. If the protein is involved in the response to Z-type α 1 -AT-induced ER stress, knockout of the coding gene should increase the susceptibility of the cells to Z-type α 1 -ATinduced cytotoxicity. In this study, the effects of CPR5 knockout on cell viability upon Z-type α 1 -AT overexpression were examined. Physical interaction between Cpr5p and Ztype α 1 -AT was confirmed by co-immunoprecipitation analysis, and the contributions of Cpr5p in Z-type α 1 -AT protein folding were analyzed.
Experimental
Strains and Reagents. Human α 1 -AT was overexpressed in S. cerevisiae BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) and the derived cpr5Δ strain (Open Biosystems Inc., Huntsville, AL, USA). Escherichia coli BL21 (DE3) was from Novagen Inc. α 1 -AT Expression in Yeasts. pYInu-AT (for human wildtype α 1 -AT expression) and pYInu-ATZ (for human Z-type α 1 -AT expression) was used to express human α 1 -AT in S. cerevisiae. 29 These plasmids contain an inulinase (Inu) signal sequence under the control of the yeast GAL10p promoter. Wild-type BY4741 and the derived cpr5Δ yeast strain were transformed with pYInu-AT or pYInu-ATZ using the standard lithium acetate method. Complementation Analysis. The CPR5 gene was amplified from S. cerevisiae Y2805 (MATa pep4::HIS3 prb1-d can1 GAL2 his3 ura3-52) genomic DNA by polymerase chain reaction (PCR) using Pfu polymerase (Promega Co., Madison, WI, USA). The forward primer was 5'-CTCCAAGCTTAT GAAACTTCAATTTTTTTCCTTTATTACCTTATTTGCTT-3' and the reverse primer was 5'-TCCAAAGCTTTTAGAGTT CATCGTGGGCTGCTTCG-3'. The PCR products were digested using HindIII and cloned into the HindIII sites of a yeast expression vector, pACT2 AD (Clontech Laboratories Inc., Mountain View, CA, USA), for the constitutive expression of Cpr5p. The resulting plasmid was named pACT2-CPR5. The cpr5Δ yeast strain was co-transformed with pYInu-ATZ and pACT2-CPR5, and the co-transformants were selected in drop-out medium lacking leucine and uracil at 30 o C for 3-4 days. Cell growth upon the expression of Z-type α 1 -AT was monitored by a spotting assay, as described above.
Co-immunoprecipitation of Cpr5p and Z-type α 1 -AT from Cell Extracts. The cpr5Δ yeast strain harboring pYInu-ATZ and/or pACT2-CPR5 was cultured in YPGal liquid medium at 30 o C for 48 h. The cultured cells were harvested and resuspended in 1 mL of lysis buffer (50 mM HEPES, pH 7.0, 1% Triton X-100, 1 mM PMSF, and 1 μM aprotinin). Cells were lysed by vigorous vortex with glass beads (425-600 μm in diameter), and the cell extracts were precleared with Protein A/G PLUS-Agarose beads at 4 o C for 2 h. Crude lysates were then incubated with polyclonal rat anti-Cpr5p antibodies (1:100 dilution) at 4 o C overnight. Immune complexes were incubated with Protein A/G PLUSAgarose beads for 2 h then collected by centrifugation. The immunoprecipitates were washed four times with IP wash buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and 1 mM phenylmethylsulfonyl fluoride), and the pellet was resuspended in sodium dodecyl sulfate (SDS) sample buffer. Protein concentrations were determined using a Bio-Rad DC protein assay kit (Hercules, CA, USA). The proteins were resolved by 10% SDSpolyacrylamide gel electrophoresis (PAGE), then transferred to a nitrocellulose membrane. The blots were probed with rabbit anti-human α 1 -AT antibodies, diluted 1:1,000 in PBS containing 0.03% Tween 20 (PBST), and then with horseradish peroxidase-conjugated goat anti-rabbit IgG antibodies diluted 1:10,000 in PBST. Bound antibodies were visualized by enhanced chemiluminescence on X-ray film using luminol as the substrate.
Purification of Cpr5p Expressed in E. coli. To express Cpr5p in E. coli, the CPR5 gene without a signal sequence was amplified from S. cerevisiae Y2805 genomic DNA by PCR. The forward primer was 5'-CTCAGAATTCAAAGA GGACACGGCAGAAGATCCTGAG-3' and the reverse primer was 5'-TCCACTCGAGTTAGAGTTCATCGTGGG CTGCTTCG-3'. After digestion with EcoRI and XhoI, the CPR5-containing fragment was subcloned into the EcoRI and XhoI sites of the pET28a vector containing a polyhistidinetag at the 5' end of the coding region, generating pET28a-CPR5. E. coli BL21 (DE3) cells were transformed with pET28a-CPR5 and grown at 37 o C in LB medium containing 50 μg/ml kanamycin to an optical density at 600 nm of approximately 0.6. Cpr5p expression was then induced by adding 0.1 mM isopropyl β-D-thiogalactoside (IPTG) followed by a 3-h incubation at 37 o C. The cells were harvested and disrupted in buffer (0.1 mM phenylmethylsulfonyl fluoride, 50 mM Tris-Cl, 250 mM NaCl, and 8 mM imidazole, pH 7.9) using a Bandelin sonicator at 43% power and 90% pulse for 2.5 min. The cell lysates were cleared by centrifugation at 14,000 rpm for 30 min in a Hanil Micro 17R+ centrifuge (Hanil Science Industrial Co., Seoul, Korea). The supernatants were loaded on a Ni
2+
-NTA agarose column pre-equilibrated with binding buffer (50 mM Tris-Cl, 250 mM NaCl, and 8 mM imidazole, pH 7.9) and eluted by a linear gradient of 30-1000 mM imidazole in 50 mL of binding buffer. Purified Cpr5p protein was buffer-exchanged to IP wash buffer using a PD-10 desalting column. The concentrations of the purified proteins were measured with a Bio-Rad DC protein assay kit.
Refolding Assay for Z-type α 1 -AT. pFEAT30-ATZ was used for Z-type α 1 -AT expression as inclusion bodies in E. coli BL21 (DE3). 31 The inclusion bodies were dissolved in 6 M urea and Z-type α 1 -AT was quickly purified at 4 o C on a Q-Sepharose TM Fast Flow column equilibrated with refolding buffer (10 mM phosphate, pH 6.5, 50 mM NaCl, and 1 mM EDTA) as previously described. 29 To achieve the native conformation of α 1 -AT, 20 μg of α 1 -AT protein was incubated at 30 o C with/without an equimolar amount of purified Cpr5p. α 1 -AT folding was monitored by 10% nondenaturing gel electrophoresis in a Tris-glycine buffer system.
Results
Knockout of CPR5 Aggravated Cytotoxicity of Z-type α 1 -AT Expression in Yeast. To evaluate the effects of Cpr5p on cytotoxicity induced by Z-type α 1 -AT overexpression, human wild-type and Z-type α 1 -AT proteins were expressed under the control of the yeast GAL10p promoter in S. cerevisiae. Differential protein expression between the wild-type and Z-type variant-expressing yeast cells was analyzed using two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption ionization-time of flight tandem mass spectroscopy (MALDI-TOF-TOF). The Cpr5p protein level was 2.2-fold higher in the cells expressing Z-type α 1 -AT-compared with those expressing wild-type α 1 -AT (Shin, unpublished data). The increased expression of Cpr5p in Z-type α 1 -AT-expressing cells was also confirmed by Western blotting (Suppl. Figure  1) . If Cpr5p was involved in the cellular response to misfolded Z-type α 1 -AT accumulation within cells, deletion of the gene should impede the cellular adjustment and exacerbate cytotoxicity of Z-type α 1 -AT expression. Wildtype BY4741 and the derived CPR5 knockout yeast stains (Open Biosystems Inc.) were transformed with pYInu-AT and pYInu-ATZ to express the wild-type and Z-type α 1 -AT proteins, respectively. Expression of α 1 -AT was induced by growing cells in medium containing 2% galactose, and cell growth was visually monitored on plates spotted with serially diluted cultures. Overexpression of Z-type α 1 -AT caused only moderate cytotoxicity in wild-type yeast, but knockout of CPR5 aggravated cytotoxicity of Z-type α 1 -AT by reducing cell viability down to 47% (Figure 1 ). To confirm that the increased cytotoxicity in the cpr5Δ strain was due to knockout of the gene, CPR5 was reintroduced into the knockout strain, and cell survival recovery was monitored. When the cpr5Δ strain was co-transformed with pYInu-ATZ and pACT2-CPR5, cell survival upon Z-type α 1 -AT-expression returned to the level seen in the wild-type strain (Figure 2) . These results indicate that CPR5 is involved in cellular responses to Z-type α 1 -AT-mediated cytotoxicity.
Cpr5p Co-immunoprecipitates with Z-type α 1 -AT. To determine whether Cpr5p interacts with Z-type α 1 -AT in yeast cells, a co-immunoprecipitation study was performed in cpr5Δ cells co-transformed with pYInu-ATZ and pACT2-CPR5. Cell extracts were prepared from co-transformed cells grown in YPGal medium, followed by incubation with polyclonal rat anti-Cpr5p antibodies. Bound complexes were isolated using Protein A/G PLUS-Agarose beads, and coprecipitated Z-type α 1 -AT was detected by immunoblotting using rabbit polyclonal anti-α 1 -AT antibodies. Cpr5p coimmunoprecipitated with Z-type α 1 -AT when both Cpr5p and Z-type α 1 -AT were overexpressed (Figure 3, lane 3) , but not in the absence of pYInu-ATZ or pACT2-CPR5 transformation ( Figure 3, lanes 1 & 2) . This result shows that Cpr5p selectively interacts with Z-type α 1 -AT in co-transformed yeast cells.
Cpr5p Facilitates Folding of Z-type α 1 -AT in vitro. For in vitro refolding assays, Cpr5p was overexpressed in E. coli and purified. CPR5 without the signal sequence was amplified from yeast Y2805 genomic DNA by PCR and cloned onto the pET28a plasmid, which has an N-terminal poly-His-tag. Overexpression of Cpr5p was induced in the E. coli BL21 (DE3) strain by addition of IPTG, and the expressed (His) ntagged Cpr5p was purified by liquid column chromatography using Ni
2+
-NTA agarose beads. The purification of Cpr5p was analyzed by 12% sodium-dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis ( Figure 4) . The purified Cpr5p retained PPIase activity, which was confirmed using a traditional protease-coupled assay 32 (data not shown). The results of the PPIase activity assay and co-immunoprecipitation analysis suggest that Cpr5p reduces Z-type α 1 -AT-induced cytotoxicity by interacting with Z-type α 1 -AT and assisting protein folding.
To further explore this possibility, Z-type α 1 -AT was overexpressed in inclusion bodies and purified in its unfolded form. Unfolded Z-type α 1 -AT was allowed to refold in the absence/presence of Cpr5p, and its folding was assessed by native gel electrophoresis. As previously reported, folding of the wild-type α 1 -AT occurred immediately ( Figure 5 , lane 6), while that of Z-type α 1 -AT was very slow 11 ( Figure 5,  lanes 2-5) . However, addition of Cpr5p accelerated the folding of Z-type α 1 -AT into its native form ( Figure 5 , lanes The cpr5Δ yeast strains harboring pYInu-ATZ and/or pACT2-CPR5 were cultured in YPGal liquid medium. The cell extracts were incubated with polyclonal anti-Cpr5p antibodies (diluted 1:100), and immune complexes were precipitated using Protein A/ G PLUS-Agarose beads. The precipitated proteins were resolved on 10% SDS-polyacrylamide gels and analyzed by immunoblotting using rabbit polyclonal anti-human α1-AT antibodies. 7-10), suggesting that Cpr5p rescued the Z-type α 1 -AT variant from retarded protein folding.
Discussion
The lumen of the ER is a specialized subcellular compartment for folding of secreted or membrane proteins. Quality control machinery in the ER allows for the advancement of properly folded proteins only via secretory pathways. Misfolded proteins are either retained in the ER or redirected to the cytosol for ER-associated degradation (ERAD). Most unstable α 1 -AT variants are degraded via ERAD and consequently fail to reach the plasma, leading to pulmonary emphysema. Meanwhile, the Z-type α 1 -AT variant has been reported to fold very slowly and to accumulate as folding intermediates prone to intermolecular loop-sheet polymerization.
11 Accumulation of misfolded Z-type α 1 -AT in the ER induces cell death, leading to liver cirrhosis in addition to pulmonary emphysema. The native form of Ztype α 1 -AT, once folded, exhibits significant stability and activity. Thus, in this study, we pursued an approach to resolve the slow folding issues associated with Z-type α 1 -AT by aids from folding assistant proteins. Cpr5p was induced by Z-type α 1 -AT expression in yeast, and knockout of CPR5 aggravated the cytotoxicity of Z-type α 1 -AT (Figure 1 ), suggesting that Cpr5p is involved in the cellular response to Z-type α 1 -AT accumulation. Interaction between Cpr5p and Z-type α 1 -AT was confirmed by co-immunoprecipitation ( Figure 3) . Purified Cpr5p accelerated folding of Z-type α 1 -AT in vitro ( Figure 5 ), though to a lesser extent compared with another ER cyclophilin, Cpr2p. 29 The result suggests the presence of other components of folding complex which are required for full-folding activity. Indeed, the human ortholog of Cpr5p, hCypB, exists in a complex with other chaperones, 33 suggesting that it cooperates with other folding assistant proteins to protect cells against ER stress. In vitro folding assays without other cooperating chaperones might limit the degree of facilitation of Z-type α 1 -AT folding by Cpr5p. However, exacerbated cytotoxicity in the CPR5 knockout strain (Figure 1 ) and recovery from the sensitized phenotype upon Cpr5p expression (Figure 2 ) suggest that Cpr5p plays significant role(s) in vivo in the response to Ztype α 1 -AT accumulation, possibly by facilitating folding through cooperation with other chaperones in the complex.
Cis-trans isomerization of X-Pro peptide bonds is extremely slow and considered to be a rate limiting step in protein folding, 34 which can be accelerated by PPIases. There are several previous studies suggesting that Cpr5p homologues are involved in folding of secreted or membrane proteins: Drosophila ninaA was shown to be essential in the secretion of rhodopsin Rh1 from photoreceptor cells;
25 the folding of procollagen I and subsequent production of secreted collagen I were decreased by cyclosporine A, an inhibitor of hCypB, in chick embryonic fibroblast cultures;
26 reduction of hCypB levels by siRNA-mediated knockdown or cyclosporin A treatment decreased the secretion of active ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat); 35 and siRNA-mediated knockdown of hCypB also significantly increased ER stress-induced apoptosis upon tunicamycin treatment. 24 Considering that hCypB is the most abundant cyclophilin in the ER and has highly conserved sequences among organisms, it is likely to play a crucial role in the management of protein folding in the ER.
ER stress has been implicated in the pathology of several protein folding diseases, such as Alzheimer's disease, Parkinson's disease, and polyglutamine-induced aggregation diseases. [36] [37] [38] Further studies would provide a better understanding of the biological function of ER chaperones and their possible contribution to the proper folding of these disease-associated proteins, which might enable the development of novel therapeutic strategies. The knowledge obtained through this study might aid in the identification of new therapeutic targets for prevention/treatment of folding diseases, including Z-type α 1 -AT-induced liver cirrhosis. 
